k141_9936_11	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	28.3	191	249	343	5.69e-19	83.6
k141_9936_11	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	31.4	191	249	307	6.96e-18	80.1
k141_9936_64	SARG|gb|WP_082039181.1|ARO:3007028|salD	28.1	185	268	544	9.35e-08	51.6
k141_9936_122	SARG|DQ212986.1.gene3.p01	59.2	71	71	75	1.16e-22	81.3
k141_39375_10	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	54.3	1223	1242	1162	0.0	1214
k141_39375_10	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	53.0	1230	1242	1186	0.0	1177
k141_39375_10	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	53.0	1230	1242	1186	0.0	1177
k141_39375_19	NCBI|CBE03766.1|1|1|nimB-Cd|nimB-Cd||1|NITROIMIDAZOLE|NITROIMIDAZOLE|putative_5-nitroimidazole_reductase_NimB-Cd|AMR|nitroimidazole	48.1	156	155	155	8.65e-41	133
k141_39375_19	NCBI|WP_005812825.1|1|1|nimJ|nimJ|nitroimidazole_reductase|2|NITROIMIDAZOLE|NITROIMIDAZOLE|5-nitroimidazole_reductase_NimJ|AMR|nitroimidazole	31.8	157	155	165	7.34e-22	85.1
k141_39375_38	SARG|NP_878015	35.8	254	316	322	2.55e-34	126
k141_39375_38	SARG|gi|749574782|ref|WP_040203616.1|	35.8	260	316	323	3.62e-34	126
k141_39375_38	SARG|FJ349556.1.gene5.p01	32.6	298	316	326	7.49e-34	125
k141_39375_38	NCBI|WP_011029109.1|1|1|vanH-Sc|vanH-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Sc|AMR|glycopeptide	34.2	295	316	337	2.51e-33	124
k141_39375_38	SARG|AAY52004	33.0	291	316	322	7.08e-33	122
k141_39375_38	SARG|KF478993.1.gene2.p01	32.6	276	316	350	2.32e-32	122
k141_39375_38	NCBI|WP_063856710.1|1|1|vanH-Pt2|vanH-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Pt2|AMR|glycopeptide	35.6	233	316	322	2.67e-32	121
k141_39375_38	NCBI|WP_063856698.1|1|1|vanH-Ac1|vanH-Ac1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ac1|AMR|glycopeptide	32.6	307	316	351	3.29e-31	119
k141_39375_38	NCBI|WP_063856700.1|1|1|vanH-Ao2|vanH-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao2|AMR|glycopeptide	32.4	299	316	343	1.48e-30	117
k141_39375_38	NCBI|WP_063856699.1|1|1|vanH-Ao1|vanH-Ao1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao1|AMR|glycopeptide	32.4	299	316	348	1.61e-30	117
k141_39375_54	SARG|gi|751264306|ref|WP_040974017.1|	38.8	219	255	646	1.64e-43	154
k141_39375_54	SARG|gi|985815823|ref|WP_060876116.1|	38.1	215	255	646	3.12e-43	154
k141_39375_54	SARG|YP_002239469	38.1	215	255	646	3.12e-43	154
k141_39375_54	SARG|gi|695840638|ref|WP_032753940.1|	38.1	215	255	646	3.12e-43	154
k141_39375_54	SARG|gi|556492128|ref|WP_023339842.1|	38.1	215	255	646	3.12e-43	154
k141_39375_54	SARG|gi|556337683|ref|WP_023297316.1|	38.6	215	255	646	4.31e-43	153
k141_39375_54	SARG|gi|763399392|ref|WP_044256358.1|	37.9	219	255	648	4.38e-43	153
k141_39375_54	SARG|gi|852138723|ref|WP_048293411.1|	38.1	215	255	646	5.95e-43	153
k141_39375_54	SARG|gi|1000904163|ref|WP_061155197.1|	38.1	215	255	646	5.95e-43	153
k141_39375_54	SARG|gi|765283866|ref|WP_044612790.1|	38.1	215	255	646	5.95e-43	153
k141_127079_4	SARG|gi|542061059|gb|ERI11611.1|	39.2	217	292	316	6.37e-41	143
k141_127079_4	SARG|P42332	39.9	208	292	306	2.09e-39	139
k141_127079_4	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	39.9	208	292	306	2.09e-39	139
k141_127079_4	SARG|gi|510143239|gb|AGN36970.1|	39.9	208	292	313	2.46e-39	139
k141_127079_4	SARG|ABB80128	39.9	208	292	306	2.93e-39	138
k141_127079_4	SARG|gi|445996729|ref|WP_000074584.1|	38.7	217	292	309	3.14e-39	138
k141_127079_4	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	38.4	219	292	307	4.21e-39	138
k141_127079_4	SARG|gi|895808656|emb|COR83787.1|	38.7	217	292	309	4.41e-39	138
k141_127079_4	SARG|gi|500194536|ref|WP_011867743.1|	39.2	217	292	306	8.09e-39	137
k141_127079_4	SARG|gi|895736250|emb|COF64653.1|	38.2	217	292	309	1.21e-38	137
k141_10905_8	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	42.6	223	218	231	9.81e-50	160
k141_10905_8	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	41.3	223	218	232	3.22e-48	157
k141_10905_8	SARG|ZP_02848503	38.6	215	218	221	1.52e-43	144
k141_10905_8	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	37.2	231	218	235	2.23e-43	144
k141_10905_8	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.6	223	218	231	7.96e-43	143
k141_10905_8	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.1	223	218	231	7.96e-43	143
k141_10905_8	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	37.0	227	218	229	1.06e-42	142
k141_10905_8	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	36.7	226	218	230	1.54e-42	142
k141_10905_8	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.1	223	218	231	1.59e-42	142
k141_10905_8	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.1	223	218	231	1.59e-42	142
k141_10905_9	CARD|gb|ABD30512.1|ARO:3000839|arlS	31.3	313	479	451	1.17e-29	119
k141_10905_9	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	27.2	261	479	370	1.47e-23	100
k141_10905_9	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	26.9	286	479	365	2.54e-23	100
k141_10905_9	megares|MEG_7521|Drugs|Glycopeptide|VanN-type_regulator|VANSN_1	31.2	260	479	364	4.60e-23	99.4
k141_10905_9	NCBI|WP_063856749.1|1|1|vanS-N|vanS-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-N|AMR|glycopeptide	31.2	260	479	364	4.60e-23	99.4
k141_10905_9	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	29.2	260	479	386	1.99e-22	97.8
k141_10905_9	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	29.2	260	479	386	1.99e-22	97.8
k141_10905_9	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	29.0	279	479	368	2.20e-22	97.4
k141_10905_9	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	28.9	266	479	367	5.38e-22	96.3
k141_10905_9	NCBI|WP_063856741.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	29.4	265	479	386	8.95e-22	95.9
k141_10905_25	CARD|gb|AAN28945.1|ARO:3003785|Ctra_murA_FOF	31.1	434	418	444	3.70e-54	185
k141_10905_71	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	43.0	230	236	231	5.48e-54	172
k141_10905_71	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	39.9	228	236	232	1.02e-51	166
k141_10905_71	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	39.9	228	236	232	1.02e-51	166
k141_10905_71	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	39.7	229	236	232	1.84e-49	160
k141_10905_71	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.9	229	236	231	1.43e-48	158
k141_10905_71	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	38.0	229	236	229	1.90e-48	158
k141_10905_71	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.9	229	236	231	2.85e-48	157
k141_10905_71	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	37.9	232	236	235	4.51e-48	157
k141_10905_71	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.2	228	236	231	5.69e-48	157
k141_10905_71	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.0	229	236	231	3.20e-47	155
k141_10905_72	CARD|gb|ABD30512.1|ARO:3000839|arlS	27.2	313	492	451	5.61e-25	106
k141_10905_72	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	29.0	221	492	359	4.38e-21	93.6
k141_10905_72	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	25.0	228	492	380	4.42e-20	90.9
k141_10905_72	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	25.0	228	492	380	4.42e-20	90.9
k141_10905_94	SARG|gb|WP_104671188.1|ARO:3003948|efrA	39.5	575	580	575	1.28e-120	367
k141_10905_94	SARG|gb|AAK76137.1|ARO:3000024|patA	34.3	543	580	564	3.75e-94	298
k141_10905_94	SARG|gb|AAC74000.1|ARO:3003950|msbA	28.3	569	580	582	2.98e-68	230
k141_10905_94	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	29.9	582	580	579	2.10e-65	223
k141_10905_94	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	30.1	592	580	579	2.92e-65	222
k141_10905_94	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	27.9	551	580	574	1.21e-54	193
k141_10905_94	SARG|gi|739906046|ref|WP_037756452.1|	27.1	550	580	620	1.58e-51	186
k141_10905_94	SARG|gi|860594225|ref|WP_048475168.1|	26.5	573	580	620	1.58e-51	186
k141_10905_94	SARG|gi|948137056|ref|WP_056795395.1|	27.3	561	580	602	1.66e-51	185
k141_10905_94	SARG|gi|917229923|ref|WP_051836635.1|	27.1	539	580	620	2.98e-51	185
k141_10905_95	SARG|gb|AAK76136.1|ARO:3000025|patB	34.0	577	583	588	3.66e-107	333
k141_10905_95	SARG|gb|AYV52072.1|ARO:3002882|lmrD	35.6	497	583	664	1.66e-104	328
k141_10905_95	SARG|gi|860594225|ref|WP_048475168.1|	34.1	504	583	620	1.96e-96	306
k141_10905_95	SARG|gi|926376632|ref|WP_053705806.1|	34.5	504	583	620	2.95e-95	303
k141_10905_95	SARG|gi|1045390184|ref|WP_065479071.1|	32.1	580	583	605	1.10e-94	301
k141_10905_95	SARG|gi|663330365|ref|WP_030329892.1|	32.6	583	583	607	1.63e-94	300
k141_10905_95	SARG|gi|917155568|ref|WP_051762280.1|	33.9	504	583	620	2.26e-94	300
k141_10905_95	SARG|gi|799286378|ref|WP_045936958.1|	34.1	504	583	620	3.17e-94	300
k141_10905_95	SARG|gi|917127754|ref|WP_051734466.1|	34.1	504	583	620	3.17e-94	300
k141_10905_95	SARG|gi|926294973|ref|WP_053631154.1|	34.1	504	583	620	3.17e-94	300
k141_10905_98	SARG|AJ514254.gene.p01	22.3	676	691	640	2.01e-47	176
k141_10905_98	SARG|ABI81214	25.0	657	691	639	1.70e-44	168
k141_10905_98	SARG|X04388.gene.p01	24.7	657	691	639	3.13e-44	167
k141_10905_98	SARG|YP_002738300	24.8	657	691	639	5.77e-44	166
k141_10905_98	SARG|ABB70054	24.8	657	691	639	1.44e-43	165
k141_10905_98	SARG|BAB71968	24.2	657	691	639	4.84e-43	164
k141_10905_98	SARG|gi|319894056|gb|ADV76307.1|	24.4	660	691	639	2.20e-42	162
k141_10905_98	SARG|AM180355.1.gene636.p01	23.7	659	691	639	7.38e-42	160
k141_10905_98	SARG|FN594949.1.gene24.p01	22.3	656	691	640	1.51e-40	156
k141_79007_14	SARG|AAD42183	32.1	137	385	322	7.75e-12	64.7
k141_79007_14	SARG|AAR37059	29.4	136	385	323	7.80e-12	64.7
k141_79007_14	SARG|AAD41881	30.9	136	385	323	1.05e-11	64.3
k141_79007_14	SARG|AY082011.1.gene6.p01	27.4	237	385	323	1.05e-11	64.3
k141_79007_14	SARG|gi|552942232|ref|WP_023043160.1|	27.4	237	385	323	1.88e-11	63.5
k141_79007_14	SARG|AAD51059	30.9	136	385	323	1.88e-11	63.5
k141_79007_15	SARG|gb|CAE00499.1|ARO:3003835|cdeA	40.0	425	445	441	1.48e-100	306
k141_79007_18	SARG|gi|1006223553|ref|WP_061745579.1|	23.3	425	444	451	1.40e-32	127
k141_79007_18	SARG|ZP_03986195	23.9	426	444	451	2.64e-32	126
k141_79007_18	SARG|gi|446573695|ref|WP_000651041.1|	23.9	426	444	451	2.64e-32	126
k141_79007_18	SARG|gi|686432388|ref|WP_031921070.1|	23.7	426	444	451	3.61e-32	126
k141_79007_18	SARG|gi|446573690|ref|WP_000651036.1|	23.7	426	444	451	9.28e-32	125
k141_79007_18	SARG|gi|686408548|ref|WP_031913080.1|	23.5	426	444	451	1.27e-31	124
k141_79007_18	SARG|gi|686304329|ref|WP_031867798.1|	23.5	426	444	451	1.27e-31	124
k141_79007_18	SARG|YP_302230	24.1	427	444	451	8.33e-31	122
k141_79007_18	SARG|gb|CAE00499.1|ARO:3003835|cdeA	21.9	420	444	441	4.34e-25	105
k141_79077_6	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	39.3	201	226	233	2.44e-47	155
k141_79077_6	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	39.3	201	226	231	2.06e-45	150
k141_79077_6	CARD|gb|ATC67679.1|ARO:3000838|arlR	35.2	219	226	219	7.32e-40	135
k141_79077_6	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.1	222	226	219	1.62e-38	132
k141_79077_6	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.1	222	226	219	2.29e-38	131
k141_79077_6	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.1	222	226	220	2.35e-38	131
k141_79077_6	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.1	222	226	220	3.31e-38	131
k141_79077_6	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.6	222	226	220	3.31e-38	131
k141_79077_6	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	38.5	200	226	225	2.11e-37	129
k141_79077_6	SARG|ZP_02848503	34.2	225	226	221	6.49e-35	122
k141_79077_7	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	28.4	211	381	364	6.96e-22	94.7
k141_79077_7	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	28.4	211	381	364	6.96e-22	94.7
k141_79077_7	CARD|gb|ADM92606.1|ARO:3000549|adeS	24.3	304	381	361	3.68e-20	89.7
k141_79077_7	megares|MEG_7521|Drugs|Glycopeptide|VanN-type_regulator|VANSN_1	26.1	207	381	364	6.61e-18	83.2
k141_79077_7	NCBI|WP_063856749.1|1|1|vanS-N|vanS-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-N|AMR|glycopeptide	26.1	207	381	364	6.61e-18	83.2
k141_79077_39	SARG|gi|851935911|ref|WP_048224705.1|	33.3	279	306	660	7.85e-42	152
k141_79077_39	SARG|gi|851917461|ref|WP_048217311.1|	33.3	279	306	660	1.08e-41	151
k141_79077_39	SARG|gi|489117806|ref|WP_003027650.1|	33.3	279	306	660	1.08e-41	151
k141_79077_39	SARG|gi|765458296|ref|WP_044714032.1|	33.3	279	306	660	1.08e-41	151
k141_79077_39	SARG|gi|696375142|ref|WP_032949690.1|	33.3	279	306	660	1.08e-41	151
k141_79077_39	SARG|gi|507079934|ref|WP_016150692.1|	33.0	279	306	660	3.85e-41	150
k141_79077_39	SARG|gi|757799830|ref|WP_043017032.1|	33.3	279	306	660	5.29e-41	149
k141_79077_39	SARG|gi|507086291|ref|WP_016157032.1|	34.1	279	306	660	7.27e-41	149
k141_79077_39	SARG|gi|489931383|ref|WP_003834702.1|	33.3	279	306	660	7.27e-41	149
k141_79077_39	SARG|gi|1002399350|ref|WP_061382108.1|	33.3	279	306	660	9.99e-41	149
k141_79077_44	CARD|gb|WKR28567.1|ARO:3007678|IreK	36.0	594	702	718	2.14e-88	291
k141_79077_76	SARG|gb|AAC75314.1|ARO:3003578|pmrF	28.5	316	318	322	9.51e-36	130
k141_79077_105	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	23.2	867	804	1024	6.08e-32	132
k141_79077_105	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	23.2	867	804	1024	6.08e-32	132
k141_79077_105	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	23.2	867	804	1024	6.08e-32	132
k141_79077_105	SARG|gb|CAA53189|ARO:3000521|mupA	23.2	867	804	1024	6.08e-32	132
k141_79077_105	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	21.5	840	804	1033	4.44e-28	120
k141_79077_105	SARG|gb|AEY83581|ARO:3000510|mupB	21.5	840	804	1033	4.44e-28	120
k141_79077_105	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	21.7	699	804	1107	1.42e-14	77.0
k141_79077_105	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	21.7	699	804	1107	1.42e-14	77.0
k141_79077_122	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	30.3	866	922	1024	4.06e-125	402
k141_79077_122	SARG|gb|CAA53189|ARO:3000521|mupA	30.3	866	922	1024	4.06e-125	402
k141_79077_122	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	30.3	866	922	1024	5.66e-125	402
k141_79077_122	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	30.3	866	922	1024	5.66e-125	402
k141_79077_122	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	29.4	897	922	1033	5.64e-114	373
k141_79077_122	SARG|gb|AEY83581|ARO:3000510|mupB	29.4	897	922	1033	5.64e-114	373
k141_79077_142	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	25.2	230	328	346	5.89e-12	64.7
k141_79077_148	SARG|gb|MBW0770001.1|ARO:3007026|salB	21.2	501	888	541	7.94e-21	96.3
k141_79077_148	SARG|U82085.gene.p01	25.0	547	888	552	2.44e-19	91.7
k141_79077_148	SARG|gb|ABX00624.1|ARO:3002881|lmrC	26.4	557	888	550	2.84e-17	85.1
k141_79077_148	SARG|gb|WP_096809342.1|ARO:3007029|salE	28.4	183	888	543	8.99e-14	73.9
k141_79077_148	SARG|gi|445996724|ref|WP_000074579.1|	28.8	212	888	309	1.01e-13	72.0
k141_79077_148	SARG|gi|1043490477|ref|WP_065382463.1|	28.8	212	888	309	1.01e-13	72.0
k141_79077_148	SARG|gi|445996726|ref|WP_000074581.1|	28.8	212	888	309	1.01e-13	72.0
k141_79077_148	SARG|gi|447057509|ref|WP_001134765.1|	28.3	212	888	309	1.01e-13	72.0
k141_79077_148	SARG|gi|445996723|ref|WP_000074578.1|	28.8	212	888	309	1.01e-13	72.0
k141_79077_148	SARG|gi|507054395|ref|WP_016125339.1|	28.8	212	888	309	1.01e-13	72.0
k141_79077_158	SARG|L20800.gene.p01	28.9	454	529	652	5.64e-37	144
k141_79077_158	SARG|NP_348076	28.4	451	529	652	1.03e-36	143
k141_79077_158	SARG|YP_002850805	28.9	453	529	652	2.56e-36	142
k141_79077_158	SARG|ZP_02952732	28.6	454	529	652	2.56e-36	142
k141_79077_158	SARG|ZP_02632674	28.6	454	529	660	2.69e-36	142
k141_79077_158	SARG|Q08425	29.1	454	529	641	1.64e-34	136
k141_79077_158	megares|MEG_7181|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	29.1	454	529	657	1.79e-34	136
k141_79077_158	SARG|Z21523.gene.p01	29.1	454	529	657	1.79e-34	136
k141_79077_158	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	28.9	454	529	654	5.83e-34	135
k141_79077_158	megares|MEG_7182|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	28.9	454	529	670	6.30e-34	135
k141_52049_15	ResF|mre(A)_1_U92073_1	33.6	283	311	310	1.05e-38	137
k141_52049_15	SARG|gb|AAB64408.1|ARO:3007050|mreA	33.6	283	311	311	1.07e-38	137
k141_52049_20	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	28.5	435	604	629	5.58e-30	124
k141_52049_20	ResF|tet(O/W)_3_AM889120_1	28.5	435	604	639	5.84e-30	124
k141_52049_20	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	28.5	435	604	629	1.33e-29	122
k141_52049_20	ResF|tet(O/W)_4_AM889121_1	28.5	435	604	639	1.39e-29	122
k141_52049_20	megares|MEG_7173|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	28.3	435	604	629	2.38e-29	122
k141_52049_20	ResF|tet(O/W)_1_AM889118_1	28.3	435	604	639	2.49e-29	122
k141_52049_20	SARG|AAO42740	28.5	435	604	639	3.32e-29	121
k141_52049_20	SARG|AY485126.gene.p01	28.5	435	604	639	3.32e-29	121
k141_52049_20	megares|MEG_7175|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	28.5	435	604	639	3.32e-29	121
k141_52049_20	megares|MEG_7163|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	28.5	435	604	629	4.25e-29	121
k141_3022_1	CARD|gb|CYF42523.1|ARO:3004047|kdpD	30.7	792	789	885	2.36e-125	395
k141_3022_2	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	47.3	203	208	225	2.70e-56	177
k141_3022_2	CARD|gb|AAC73788.1|ARO:3003841|kdpE	47.3	203	208	225	2.70e-56	177
k141_3022_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	37.9	203	208	219	1.30e-38	131
k141_3022_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	33.7	208	208	231	4.83e-35	122
k141_3022_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	35.0	206	208	232	9.84e-35	122
k141_3022_2	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	35.0	206	208	232	9.84e-35	122
k141_3022_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	34.0	203	208	228	1.77e-34	121
k141_3022_2	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	31.0	203	208	229	2.55e-34	120
k141_3022_2	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.4	204	208	231	1.49e-33	119
k141_3022_2	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.4	204	208	231	5.85e-33	117
k141_138895_14	CARD|gb|CYF42523.1|ARO:3004047|kdpD	28.5	656	659	885	4.43e-79	268
k141_138895_14	CARD|gb|AEX49906.1|ARO:3003583|basS	25.9	239	659	477	2.09e-15	78.2
k141_138895_14	CARD|gb|ADM92606.1|ARO:3000549|adeS	24.1	220	659	361	4.48e-11	63.9
k141_138895_15	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	44.9	225	234	225	9.36e-64	197
k141_138895_15	CARD|gb|AAC73788.1|ARO:3003841|kdpE	44.9	225	234	225	9.36e-64	197
k141_138895_15	CARD|gb|ATC67679.1|ARO:3000838|arlR	36.9	222	234	219	9.53e-43	143
k141_138895_15	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	34.1	226	234	232	2.15e-41	140
k141_138895_15	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	34.1	226	234	232	2.15e-41	140
k141_138895_15	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	35.1	228	234	231	2.95e-41	139
k141_138895_15	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	33.2	223	234	231	1.30e-39	135
k141_138895_15	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	31.5	222	234	229	2.44e-39	134
k141_138895_15	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	33.3	228	234	232	2.65e-39	134
k141_138895_15	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	33.2	223	234	231	3.63e-39	134
k141_138895_28	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	29.2	277	383	355	4.08e-19	86.7
k141_138895_28	SARG|BAE96115	29.2	277	383	355	4.08e-19	86.7
k141_138895_28	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	28.9	277	383	355	1.86e-18	84.7
k141_138895_28	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	28.9	277	383	355	1.86e-18	84.7
k141_138895_28	SARG|ACM47285	28.9	277	383	363	2.00e-18	84.7
k141_138895_28	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	31.4	194	383	209	1.07e-13	68.6
k141_149760_22	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.8	624	638	655	7.91e-118	364
k141_149760_22	SARG|gb|AKA86814|ARO:3003746|optrA	34.8	624	638	655	7.91e-118	364
k141_149760_22	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.8	624	638	655	3.10e-117	363
k141_149760_22	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.8	624	638	655	3.10e-117	363
k141_149760_22	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.8	624	638	655	4.36e-117	362
k141_149760_22	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.8	624	638	655	6.14e-117	362
k141_149760_22	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.8	624	638	655	6.14e-117	362
k141_149760_22	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.8	624	638	655	8.64e-117	362
k141_149760_22	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.8	624	638	655	8.64e-117	362
k141_149760_22	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.8	624	638	655	1.22e-116	361
k141_53569_7	NCBI|WP_011906899.1|1|1|estDL136|estDL136||2|CHLORAMPHENICOL/FLORFENICOL|PHENICOL|phenicol_hydrolase|AMR|phenicol	36.7	109	283	308	3.11e-14	70.5
k141_53569_24	SARG|gi|445996719|ref|WP_000074574.1|	39.3	219	319	309	1.73e-48	163
k141_53569_24	SARG|gi|447195835|ref|WP_001273091.1|	32.3	319	319	306	4.45e-48	162
k141_53569_24	SARG|gi|445996723|ref|WP_000074578.1|	39.3	219	319	309	9.50e-48	161
k141_53569_24	SARG|gi|447195836|ref|WP_001273092.1|	32.0	319	319	306	1.24e-47	161
k141_53569_24	SARG|gi|445996710|ref|WP_000074565.1|	38.4	219	319	309	1.34e-47	161
k141_53569_24	SARG|gi|445996722|ref|WP_000074577.1|	38.8	219	319	309	1.34e-47	161
k141_53569_24	SARG|gi|1043490477|ref|WP_065382463.1|	38.8	219	319	309	2.64e-47	160
k141_53569_24	SARG|gi|445996726|ref|WP_000074581.1|	38.8	219	319	309	2.64e-47	160
k141_53569_24	SARG|gi|884875933|emb|CKG93789.1|	38.4	219	319	309	2.64e-47	160
k141_53569_24	SARG|gi|507054395|ref|WP_016125339.1|	38.8	219	319	309	2.64e-47	160
k141_53569_28	SARG|gb|AAC75314.1|ARO:3003578|pmrF	30.4	309	325	322	5.57e-37	134
k141_53569_56	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	43.9	677	692	703	1.06e-161	481
k141_53569_69	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	28.4	479	674	633	1.13e-45	171
k141_53569_82	SARG|gb|MBY8651253.1|ARO:3007189|vanP	31.2	356	356	342	8.80e-38	137
k141_53569_83	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	37.5	456	451	481	8.11e-97	298
k141_53569_83	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	37.4	452	451	451	3.33e-94	290
k141_53569_83	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	36.6	451	451	451	3.70e-93	288
k141_53569_95	CARD|gb|ABD30512.1|ARO:3000839|arlS	28.3	382	524	451	1.82e-33	131
k141_53569_95	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	28.1	288	524	370	1.13e-29	119
k141_53569_95	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.6	248	524	381	1.35e-29	119
k141_53569_95	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.6	248	524	381	1.35e-29	119
k141_53569_95	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	30.2	242	524	367	1.47e-29	118
k141_53569_95	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	30.2	242	524	368	1.49e-29	118
k141_53569_95	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.2	248	524	381	3.41e-29	117
k141_53569_95	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.2	248	524	381	3.41e-29	117
k141_53569_95	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.6	250	524	381	8.63e-29	116
k141_53569_95	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.6	250	524	381	8.63e-29	116
k141_53569_96	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	38.2	225	228	231	1.48e-54	173
k141_53569_96	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	38.4	229	228	232	4.31e-54	172
k141_53569_96	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	38.4	229	228	232	4.31e-54	172
k141_53569_96	CARD|gb|ATC67679.1|ARO:3000838|arlR	35.7	224	228	219	1.17e-53	171
k141_53569_96	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	36.3	226	228	232	7.82e-52	166
k141_53569_96	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	35.1	228	228	229	1.01e-51	166
k141_53569_96	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	37.0	227	228	231	4.86e-50	162
k141_53569_96	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	37.2	231	228	235	1.54e-49	160
k141_53569_96	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	37.3	228	228	231	5.48e-49	159
k141_53569_96	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	37.3	228	228	231	7.75e-49	159
k141_53569_114	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	43.4	219	243	343	3.09e-55	179
k141_53569_114	SARG|gb|AAA26793|ARO:3003748|oleC	40.4	218	243	325	1.10e-47	159
k141_53569_114	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	40.4	218	243	325	1.10e-47	159
k141_53569_114	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	36.5	230	243	293	2.66e-40	139
k141_53569_114	SARG|gi|500465078|gb|EOP76697.1|	38.8	219	243	306	1.41e-39	137
k141_53569_114	SARG|gi|500448961|gb|EOP61695.1|	38.8	219	243	306	1.98e-39	137
k141_53569_114	SARG|gi|1043490477|ref|WP_065382463.1|	38.8	219	243	309	1.63e-38	135
k141_53569_114	SARG|gi|445996726|ref|WP_000074581.1|	38.8	219	243	309	1.63e-38	135
k141_53569_114	SARG|gi|884875933|emb|CKG93789.1|	38.8	219	243	309	1.63e-38	135
k141_53569_114	SARG|gi|445996723|ref|WP_000074578.1|	38.8	219	243	309	1.63e-38	135
k141_53569_129	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.1	207	405	381	2.10e-18	85.1
k141_53569_129	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.1	207	405	381	2.10e-18	85.1
k141_53569_129	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.4	205	405	381	1.26e-17	82.8
k141_53569_129	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	23.7	207	405	381	1.26e-17	82.8
k141_53569_129	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.4	205	405	381	1.26e-17	82.8
k141_53569_129	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	23.7	207	405	381	1.26e-17	82.8
k141_53569_129	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	24.2	211	405	380	1.68e-17	82.4
k141_53569_129	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	24.2	211	405	380	1.68e-17	82.4
k141_53569_129	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	22.9	205	405	381	3.07e-17	81.6
k141_53569_129	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	22.9	205	405	381	3.07e-17	81.6
k141_53569_130	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	31.4	207	202	223	6.79e-31	111
k141_53569_130	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	30.6	206	202	232	2.55e-29	107
k141_53569_130	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	30.6	206	202	232	2.55e-29	107
k141_53569_130	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	32.2	208	202	232	1.40e-28	105
k141_53569_130	CARD|gb|AAG05188.1|ARO:3005068|ParR	30.0	203	202	235	1.50e-28	105
k141_53569_130	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	30.8	208	202	231	5.33e-28	104
k141_53569_130	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	32.6	215	202	235	3.41e-26	99.8
k141_53569_130	CARD|gb|AAD51348.1|ARO:3003066|smeR	31.0	200	202	229	5.91e-26	99.0
k141_53569_130	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	29.4	211	202	239	1.02e-25	98.6
k141_53569_130	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	28.8	208	202	231	4.70e-25	96.7
k141_53569_132	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	44.1	222	224	255	1.65e-63	197
k141_53569_132	SARG|gb|AAV85982.1|ARO:3000535|macB	44.6	224	224	644	1.15e-60	199
k141_53569_132	SARG|gi|507086196|ref|WP_016156937.1|	48.2	222	224	648	3.42e-59	196
k141_53569_132	SARG|gi|922960663|ref|WP_053388845.1|	48.2	220	224	648	4.76e-59	195
k141_53569_132	SARG|gi|504542119|ref|WP_014729221.1|	47.7	220	224	647	6.55e-59	195
k141_53569_132	SARG|gi|757799695|ref|WP_043016897.1|	48.2	220	224	648	6.64e-59	195
k141_53569_132	SARG|gi|1045891604|ref|WP_065554100.1|	48.2	220	224	648	6.64e-59	195
k141_53569_132	SARG|gi|507082903|ref|WP_016153652.1|	48.2	220	224	648	6.64e-59	195
k141_53569_132	SARG|gi|740856590|ref|WP_038641842.1|	48.2	220	224	648	6.64e-59	195
k141_53569_132	SARG|gi|851922185|ref|WP_048218206.1|	48.2	220	224	648	6.64e-59	195
k141_101351_11	SARG|gb|APB03216.1|ARO:3003982|LlmA	58.2	287	288	287	5.61e-135	382
k141_101351_12	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	31.8	239	282	343	1.79e-30	115
k141_101351_12	SARG|gi|671541568|ref|WP_031525212.1|	33.2	217	282	648	7.84e-27	108
k141_101351_12	SARG|gi|657888313|ref|WP_029592374.1|	33.5	227	282	648	6.63e-26	105
k141_101351_12	SARG|gi|639225329|ref|WP_024561799.1|	33.0	227	282	648	3.04e-25	103
k141_101351_12	SARG|gi|639218559|ref|WP_024556062.1|	33.0	227	282	648	3.04e-25	103
k141_101351_12	SARG|gi|639216333|ref|WP_024554080.1|	33.0	227	282	648	3.04e-25	103
k141_101351_12	SARG|gi|746253210|ref|WP_039301529.1|	34.7	216	282	648	4.12e-25	103
k141_101351_12	SARG|gi|1001720867|ref|WP_061274204.1|	34.3	216	282	648	7.56e-25	102
k141_101351_12	SARG|gi|495736522|ref|WP_008461101.1|	34.3	216	282	648	1.39e-24	102
k141_101351_12	SARG|gi|981224618|ref|WP_059445588.1|	31.9	238	282	646	3.44e-24	100
k141_101351_13	SARG|ZP_04081918	30.9	288	290	306	1.34e-34	126
k141_101351_13	SARG|gi|447195835|ref|WP_001273091.1|	31.0	277	290	306	3.66e-34	125
k141_101351_13	SARG|gi|445996710|ref|WP_000074565.1|	32.0	244	290	309	3.90e-34	125
k141_101351_13	SARG|gi|445996719|ref|WP_000074574.1|	32.4	225	290	309	5.45e-34	124
k141_101351_13	SARG|gi|542061059|gb|ERI11611.1|	28.8	288	290	316	6.29e-34	124
k141_101351_13	SARG|gi|447195836|ref|WP_001273092.1|	31.0	277	290	306	7.15e-34	124
k141_101351_13	SARG|gi|500194536|ref|WP_011867743.1|	30.6	288	290	306	1.00e-33	124
k141_101351_13	SARG|gi|447057509|ref|WP_001134765.1|	32.0	225	290	309	1.06e-33	124
k141_101351_13	SARG|gi|488068784|ref|WP_002140181.1|	32.0	225	290	309	1.49e-33	123
k141_101351_13	SARG|gi|445996708|ref|WP_000074563.1|	31.1	225	290	309	2.08e-33	123
k141_101351_29	SARG|AAN28721	44.1	93	389	108	6.25e-18	77.8
k141_101351_36	SARG|gi|803568669|ref|WP_046077412.1|	24.2	207	425	648	2.34e-13	70.9
k141_101351_36	SARG|gi|446110352|ref|WP_000188207.1|	24.2	207	425	648	2.34e-13	70.9
k141_101351_36	SARG|YP_002382193	24.2	207	425	648	2.34e-13	70.9
k141_101351_36	SARG|gi|803575554|ref|WP_046081557.1|	24.2	207	425	648	2.34e-13	70.9
k141_101351_36	SARG|gi|446110351|ref|WP_000188206.1|	24.2	207	425	648	2.34e-13	70.9
k141_101351_36	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	27.4	208	425	293	5.32e-13	68.2
k141_101351_36	SARG|gi|502669352|ref|WP_012905216.1|	23.4	201	425	648	2.98e-12	67.4
k141_101351_36	SARG|gb|AAR96051.1|ARO:3002894|otrC	24.4	205	425	351	3.56e-12	66.2
k141_101351_36	SARG|gi|736472622|ref|WP_034494292.1|	21.7	207	425	648	2.71e-10	61.2
k141_101351_36	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.2	225	425	655	4.78e-10	60.5
k141_101351_41	SARG|P45439	31.3	192	285	319	8.68e-14	69.3
k141_101351_41	megares|MEG_2845|Drugs|MLS|23S_rRNA_methyltransferases|ERMS_1	31.3	192	285	319	8.68e-14	69.3
k141_101351_41	SARG|L22689.1.gene1.p01	33.3	120	285	257	6.91e-12	63.2
k141_111748_5	SARG|gb|AAC75089.1|ARO:3003577|ugd	57.8	325	327	388	5.60e-133	382
k141_111748_6	SARG|gb|AAC75089.1|ARO:3003577|ugd	60.7	84	85	388	1.30e-25	96.3
k141_111982_15	SARG|gb|AAC75314.1|ARO:3003578|pmrF	31.9	94	346	322	6.85e-06	46.2
k141_111982_16	SARG|gb|AID93387.1|ARO:3004660|catB11	48.7	39	164	210	2.42e-06	44.7
k141_111982_16	SARG|AY232670.1.gene3.p01	46.2	39	164	210	6.15e-06	43.5
k141_111982_16	NCBI|WP_071846375.1|1|1|catB3|catB3|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B-3_phenicol_O-acetyltransferase_CatB3|AMR|phenicol	38.9	54	164	210	6.15e-06	43.5
k141_111982_16	SARG|gi|499386493|ref|WP_011073960.1|	46.2	39	164	210	8.38e-06	43.1
k141_111982_25	SARG|gi|447195835|ref|WP_001273091.1|	34.6	257	293	306	7.04e-36	129
k141_111982_25	SARG|gi|542061059|gb|ERI11611.1|	33.9	286	293	316	8.72e-36	129
k141_111982_25	SARG|gi|445996729|ref|WP_000074584.1|	36.7	218	293	309	1.05e-35	129
k141_111982_25	SARG|gi|445996722|ref|WP_000074577.1|	36.1	233	293	309	1.05e-35	129
k141_111982_25	SARG|gi|445996723|ref|WP_000074578.1|	35.6	233	293	309	1.47e-35	129
k141_111982_25	SARG|gi|895808656|emb|COR83787.1|	36.7	218	293	309	1.47e-35	129
k141_111982_25	SARG|gi|447195836|ref|WP_001273092.1|	34.2	257	293	306	1.93e-35	128
k141_111982_25	SARG|gi|884875933|emb|CKG93789.1|	35.6	233	293	309	2.06e-35	128
k141_111982_25	SARG|gi|445996724|ref|WP_000074579.1|	35.6	233	293	309	2.88e-35	128
k141_111982_25	SARG|gi|1043490477|ref|WP_065382463.1|	35.2	233	293	309	4.02e-35	127
k141_111982_58	SARG|gi|505177635|ref|WP_015364737.1|	26.6	418	461	451	5.16e-33	129
k141_111982_58	SARG|gi|446573718|ref|WP_000651064.1|	27.2	423	461	451	1.81e-32	127
k141_111982_58	SARG|gi|686155635|ref|WP_031787393.1|	27.2	423	461	451	3.40e-32	126
k141_111982_58	SARG|gi|488374619|ref|WP_002444004.1|	27.2	419	461	452	1.20e-31	125
k141_111982_58	SARG|gi|537465183|ref|WP_020976941.1|	27.0	418	461	451	3.04e-31	124
k141_111982_58	SARG|ZP_04679156	25.6	418	461	451	3.04e-31	124
k141_111982_58	SARG|gi|565830932|ref|WP_023914633.1|	27.8	425	461	451	4.15e-31	123
k141_111982_58	SARG|gi|1006223553|ref|WP_061745579.1|	27.0	418	461	451	4.15e-31	123
k141_111982_58	SARG|gi|446573690|ref|WP_000651036.1|	27.0	418	461	451	5.67e-31	123
k141_111982_58	SARG|gi|446573707|ref|WP_000651053.1|	27.0	418	461	451	7.75e-31	122
k141_111982_66	SARG|gi|639209604|ref|WP_024547784.1|	37.6	221	247	648	1.93e-39	143
k141_111982_66	SARG|Q83LR7	37.3	220	247	648	5.02e-39	142
k141_111982_66	SARG|gi|647325472|ref|WP_025760953.1|	37.3	220	247	648	5.02e-39	142
k141_111982_66	SARG|gi|647323678|ref|WP_025760497.1|	37.3	220	247	648	5.02e-39	142
k141_111982_66	SARG|gi|446110311|ref|WP_000188166.1|	36.8	220	247	648	6.91e-39	141
k141_111982_66	SARG|gi|1033064422|ref|WP_064375412.1|	37.7	223	247	648	6.91e-39	141
k141_111982_66	SARG|YP_403947	36.8	220	247	650	6.99e-39	141
k141_111982_66	SARG|gi|446110301|ref|WP_000188156.1|	36.8	220	247	648	1.30e-38	140
k141_111982_66	SARG|gi|1035735809|ref|WP_064572349.1|	36.8	220	247	648	1.79e-38	140
k141_111982_66	SARG|gi|974633183|ref|WP_059219858.1|	36.8	220	247	648	1.79e-38	140
k141_43776_9	SARG|gi|851928815|ref|WP_048221086.1|	24.6	207	249	648	8.97e-11	60.5
k141_43776_9	SARG|gi|780033092|ref|WP_045444768.1|	24.6	207	249	648	8.97e-11	60.5
k141_43776_9	SARG|gi|992380339|ref|WP_061067665.1|	24.5	208	249	648	1.21e-10	60.1
k141_43776_9	SARG|gi|968563772|ref|WP_058587854.1|	23.8	210	249	648	2.18e-10	59.3
k141_43776_9	SARG|gi|922960663|ref|WP_053388845.1|	24.4	205	249	648	2.18e-10	59.3
k141_43776_9	SARG|gi|757799695|ref|WP_043016897.1|	24.4	205	249	648	2.93e-10	58.9
k141_43776_9	SARG|gi|1045891604|ref|WP_065554100.1|	24.4	205	249	648	2.93e-10	58.9
k141_43776_9	SARG|gi|507082903|ref|WP_016153652.1|	24.4	205	249	648	2.93e-10	58.9
k141_43776_9	SARG|gi|696368937|ref|WP_032943949.1|	24.5	204	249	648	3.94e-10	58.5
k141_43776_9	SARG|gi|835233765|ref|WP_047410073.1|	24.0	208	249	648	3.94e-10	58.5
k141_43776_14	SARG|gi|1035670474|ref|WP_064517458.1|	32.0	244	475	648	2.90e-24	105
k141_43776_14	SARG|gi|1035717981|ref|WP_064557480.1|	32.0	244	475	648	2.90e-24	105
k141_43776_14	SARG|gi|495736522|ref|WP_008461101.1|	33.0	230	475	648	3.88e-24	104
k141_43776_14	SARG|gi|746253210|ref|WP_039301529.1|	33.0	230	475	648	5.18e-24	104
k141_43776_14	SARG|gi|1001720867|ref|WP_061274204.1|	33.0	230	475	648	6.93e-24	103
k141_43776_14	SARG|gi|671541568|ref|WP_031525212.1|	34.1	220	475	648	2.95e-23	102
k141_43776_14	SARG|gi|751930065|ref|WP_041144773.1|	33.0	227	475	648	2.95e-23	102
k141_43776_14	SARG|gi|495067432|ref|WP_007792257.1|	32.7	220	475	647	3.93e-23	101
k141_43776_14	SARG|gi|746243059|ref|WP_039291473.1|	32.2	230	475	648	7.02e-23	100
k141_43776_14	SARG|gi|639216333|ref|WP_024554080.1|	32.7	223	475	648	1.67e-22	99.8
k141_43776_23	SARG|YP_002861121	47.4	57	200	212	4.61e-09	53.1
k141_43776_23	SARG|CAP74085	33.3	87	200	210	4.06e-08	50.4
k141_43776_23	SARG|U19459.gene.p01	38.6	57	200	212	5.78e-06	44.3
k141_43776_43	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	36.5	312	304	343	6.52e-57	186
k141_43776_43	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	38.6	220	304	325	6.05e-49	164
k141_43776_43	SARG|gb|AAA26793|ARO:3003748|oleC	39.0	218	304	325	1.20e-48	164
k141_43776_43	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	38.6	210	304	293	4.77e-42	145
k141_43776_43	SARG|gb|AAR96051.1|ARO:3002894|otrC	33.3	225	304	351	4.75e-29	112
k141_43776_43	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	33.3	225	304	351	1.27e-28	111
k141_43776_43	SARG|gb|APB03219.1|ARO:3003986|TaeA	30.1	219	304	648	1.14e-15	76.3
k141_43776_43	SARG|gi|738121094|ref|WP_036079133.1|	24.9	197	304	493	2.24e-09	57.0
k141_43776_43	SARG|gi|926250866|ref|WP_053589133.1|	21.7	184	304	492	1.27e-07	51.6
k141_43776_43	SARG|gi|517611899|ref|WP_018782107.1|	22.2	180	304	492	1.27e-07	51.6
k141_43776_75	SARG|ZP_04207693	33.4	296	320	264	9.56e-29	110
k141_43776_75	SARG|ZP_04202328	33.2	295	320	263	2.53e-28	109
k141_43776_75	SARG|ZP_03041263	30.6	301	320	267	2.75e-28	109
k141_43776_75	SARG|ZP_04226949	32.8	296	320	264	5.01e-28	108
k141_43776_75	SARG|ZP_04083542	32.1	296	320	263	6.82e-28	108
k141_43776_75	SARG|ZP_04070977	32.1	296	320	263	6.82e-28	108
k141_43776_75	SARG|ZP_04232797	32.4	296	320	264	6.97e-28	108
k141_43776_75	SARG|ZP_04144736	32.8	296	320	263	9.49e-28	107
k141_43776_75	SARG|NP_831165	32.1	296	320	263	9.49e-28	107
k141_43776_75	SARG|ZP_04113961	33.2	295	320	263	9.49e-28	107
k141_24281_21	megares|MEG_7331|Drugs|Glycopeptide|VanA-type_resistance_protein|VAN_1	59.6	47	319	114	3.31e-10	55.8
k141_24281_21	CARD|gb|AAO82019.1|ARO:3004254|vanV_in_vanB_cl	59.6	47	319	114	3.31e-10	55.8
k141_24281_43	SARG|gb|AAC75271.1|ARO:3003952|yojI	29.6	223	266	547	1.73e-12	65.9
k141_24281_43	SARG|gb|AEA37904.1|ARO:3003112|lsaC	37.8	74	266	492	4.90e-08	52.4
k141_24281_56	SARG|YP_001373621	53.2	218	252	318	3.92e-76	232
k141_24281_56	SARG|gi|447057510|ref|WP_001134766.1|	53.7	218	252	309	5.98e-76	231
k141_24281_56	SARG|gi|445996732|ref|WP_000074587.1|	53.7	218	252	309	1.20e-75	231
k141_24281_56	SARG|gi|445996723|ref|WP_000074578.1|	49.6	240	252	309	1.20e-75	231
k141_24281_56	SARG|gi|445996719|ref|WP_000074574.1|	53.2	218	252	309	1.69e-75	230
k141_24281_56	SARG|gi|445996729|ref|WP_000074584.1|	53.2	218	252	309	1.69e-75	230
k141_24281_56	SARG|gi|445996722|ref|WP_000074577.1|	49.2	240	252	309	1.69e-75	230
k141_24281_56	SARG|gi|895808656|emb|COR83787.1|	53.2	218	252	309	1.69e-75	230
k141_24281_56	SARG|gi|1043490477|ref|WP_065382463.1|	49.2	240	252	309	3.40e-75	229
k141_24281_56	SARG|gi|445996726|ref|WP_000074581.1|	49.2	240	252	309	3.40e-75	229
k141_24281_57	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	43.2	227	235	229	1.77e-54	173
k141_24281_57	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	41.9	227	235	232	9.89e-52	166
k141_24281_57	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	41.9	227	235	232	9.89e-52	166
k141_24281_57	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	38.0	221	235	228	1.59e-49	160
k141_24281_57	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.9	226	235	231	9.76e-49	159
k141_24281_57	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	40.0	230	235	233	8.23e-48	156
k141_24281_57	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	38.4	224	235	230	8.50e-47	154
k141_24281_57	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.1	226	235	231	8.74e-47	154
k141_24281_57	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	38.7	230	235	232	1.79e-46	153
k141_24281_57	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	37.2	226	235	231	2.46e-46	152
k141_24281_58	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	25.5	326	463	368	1.58e-18	85.9
k141_24281_58	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	24.1	257	463	380	3.34e-17	82.0
k141_24281_58	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	24.1	257	463	380	3.34e-17	82.0
k141_24281_58	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	26.0	285	463	367	7.29e-17	80.9
k141_24281_58	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	23.4	295	463	381	6.45e-15	75.1
k141_24281_58	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	23.4	295	463	381	6.45e-15	75.1
k141_24281_58	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	21.8	307	463	392	1.23e-14	74.3
k141_24281_58	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	22.2	293	463	381	1.54e-14	73.9
k141_24281_58	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	22.2	293	463	381	1.54e-14	73.9
k141_24281_58	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	22.2	293	463	381	2.75e-14	73.2
k141_24281_60	SARG|gb|ABA71733.1|ARO:3002972|vanTG	73.7	711	713	712	0.0	1052
k141_24281_60	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	66.9	712	713	711	0.0	913
k141_24281_60	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	62.5	712	713	712	4.48e-320	886
k141_24281_60	SARG|gi|498467693|ref|WP_010773049.1|	39.4	709	713	700	1.69e-162	484
k141_24281_60	SARG|FJ872411.1.gene43.p01	38.4	705	713	702	1.79e-162	484
k141_24281_60	NCBI|WP_063856756.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	37.0	713	713	700	3.82e-148	447
k141_24281_60	NCBI|WP_063856755.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	37.3	708	713	700	8.41e-147	443
k141_24281_60	SARG|gi|657686198|ref|WP_029487032.1|	35.3	708	713	698	1.75e-145	440
k141_24281_60	SARG|AF162694.1.gene4.p01	35.3	708	713	698	2.46e-145	439
k141_24281_60	SARG|JF802084.2.gene3.p01	36.6	708	713	700	7.31e-145	438
k141_24281_61	NCBI|WP_063856783.1|1|1|vanXY-G2|vanXY-G2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-G2|AMR|glycopeptide	73.4	237	238	254	4.09e-135	379
k141_24281_61	NCBI|WP_063856782.1|1|1|vanXY-G|vanXY-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-G|AMR|glycopeptide	71.7	237	238	254	9.61e-134	375
k141_24281_61	NCBI|WP_003126779.1|1|1|vanXY-C|vanXY-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-C|AMR|glycopeptide	45.2	177	238	190	1.82e-48	157
k141_24281_61	NCBI|WP_063856799.1|1|1|vanXY-c4|vanXY-c4|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-C|AMR|glycopeptide	42.9	177	238	190	2.92e-47	154
k141_24281_61	NCBI|WP_063856805.1|1|1|vanXY-C|vanXY-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-C|AMR|glycopeptide	42.9	177	238	190	8.25e-47	152
k141_24281_61	NCBI|WP_008377360.1|1|1|vanXY-c4|vanXY-c4|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-C|AMR|glycopeptide	42.4	177	238	190	1.17e-46	152
k141_24281_61	NCBI|WP_060792852.1|1|1|vanXY-c2/3|vanXY-c2/3|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-C|AMR|glycopeptide	42.4	177	238	190	2.33e-46	151
k141_24281_61	NCBI|WP_063856795.1|1|1|vanXY-c4|vanXY-c4|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-C|AMR|glycopeptide	42.4	177	238	190	2.33e-46	151
k141_24281_61	NCBI|WP_005228842.1|1|1|vanXY-c2/3|vanXY-c2/3|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-C|AMR|glycopeptide	42.4	177	238	190	3.30e-46	151
k141_24281_61	NCBI|WP_010749757.1|1|1|vanXY-C|vanXY-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-C|AMR|glycopeptide	42.4	177	238	190	4.66e-46	150
k141_24281_62	SARG|gi|752682279|ref|WP_041330231.1|	86.0	349	350	349	3.19e-223	610
k141_24281_62	SARG|gi|1028100561|ref|WP_063856696.1|	85.4	349	350	349	4.33e-221	605
k141_24281_62	SARG|DQ212986.1.gene8.p01	84.8	349	350	349	1.02e-219	602
k141_24281_62	SARG|gi|405945042|pdb|4FU0|A	84.8	349	350	357	1.37e-219	602
k141_24281_62	SARG|AAF71281	84.5	349	350	349	5.87e-219	600
k141_24281_62	SARG|gi|765411304|ref|WP_044689514.1|	84.5	349	350	349	8.34e-219	599
k141_24281_62	NCBI|PBI24747.1|1|1|vanG-Cd|vanG-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--D-serine_ligase_VanG-Cd|AMR|glycopeptide	65.4	367	350	366	5.03e-173	484
k141_24281_62	SARG|gb|KTE89608.1|ARO:3003723|vanI	47.8	360	350	348	3.03e-101	301
k141_24281_62	SARG|gb|ABX54687.1|ARO:3002910|vanL	44.2	346	350	349	8.88e-101	300
k141_24281_62	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_5	47.4	352	350	359	1.39e-99	297
k141_24281_63	megares|MEG_7543|Drugs|Glycopeptide|VanG-type_accessory_protein|VANWG_1	87.5	273	275	281	1.20e-182	502
k141_24281_63	NCBI|WP_021419095.1|1|1|vanW-G|vanW-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-G|AMR|glycopeptide	87.5	273	275	281	1.20e-182	502
k141_24281_63	megares|MEG_7544|Drugs|Glycopeptide|VanG-type_accessory_protein|VANWG_1	87.2	273	275	281	4.89e-182	500
k141_24281_63	NCBI|WP_063856762.1|1|1|vanW-G|vanW-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-G|AMR|glycopeptide	87.2	273	275	281	4.89e-182	500
k141_24281_63	NCBI|WP_063856764.1|1|1|vanW-Pt|vanW-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-Pt|AMR|glycopeptide	51.7	267	275	271	7.08e-95	279
k141_24281_63	megares|MEG_7537|Drugs|Glycopeptide|VanA-type_accessory_protein|VANWA_1	51.7	267	275	271	1.00e-94	279
k141_24281_63	NCBI|WP_010815683.1|1|1|vanW-B|vanW-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-B|AMR|glycopeptide	50.4	272	275	275	3.26e-94	278
k141_24281_63	NCBI|WP_032489744.1|1|1|vanW-B|vanW-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-B|AMR|glycopeptide	50.4	272	275	275	4.63e-94	277
k141_24281_63	NCBI|WP_002368694.1|1|1|vanW-B|vanW-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-B|AMR|glycopeptide	50.4	272	275	275	4.63e-94	277
k141_24281_63	NCBI|WP_063856763.1|1|1|vanW-B|vanW-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-B|AMR|glycopeptide	50.0	272	275	275	2.65e-93	275
k141_24281_64	SARG|gi|515720450|ref|WP_017153050.1|	38.9	113	193	210	1.87e-16	73.2
k141_24281_64	SARG|AF155139.2.gene5.p01	32.9	149	193	206	6.58e-16	71.6
k141_24281_64	SARG|gi|1028848471|ref|WP_064017434.1|	34.5	145	193	206	1.77e-13	65.1
k141_24281_64	SARG|gi|670466162|ref|WP_031414939.1|	34.4	131	193	206	3.41e-13	64.3
k141_24281_65	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	67.5	366	370	368	1.68e-160	453
k141_24281_65	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	66.7	366	370	367	1.17e-155	441
k141_24281_65	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	62.1	367	370	380	1.64e-151	431
k141_24281_65	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	62.1	367	370	380	1.64e-151	431
k141_24281_65	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	60.4	366	370	381	2.02e-140	403
k141_24281_65	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	60.4	366	370	381	2.02e-140	403
k141_24281_65	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	60.9	366	370	381	2.32e-139	400
k141_24281_65	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	60.9	366	370	381	2.32e-139	400
k141_24281_65	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	60.4	364	370	381	2.32e-139	400
k141_24281_65	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	60.4	364	370	381	2.32e-139	400
k141_24281_66	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	86.4	235	236	235	3.13e-157	434
k141_24281_66	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	81.3	235	236	233	5.77e-148	410
k141_24281_66	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	75.7	235	236	232	1.42e-134	377
k141_24281_66	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	74.0	235	236	232	2.74e-132	371
k141_24281_66	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	73.6	235	236	232	7.85e-132	370
k141_24281_66	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	73.2	235	236	232	2.25e-131	369
k141_24281_66	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	73.6	235	236	232	4.53e-131	368
k141_24281_66	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	73.2	235	236	232	6.43e-131	367
k141_24281_66	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	66.4	232	236	239	7.93e-115	327
k141_24281_66	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	63.4	235	236	231	3.13e-110	315
k141_24281_67	SARG|DQ212986.1.gene3.p01	80.6	72	76	75	4.67e-37	117
k141_113329_62	SARG|gb|AAB53445.1|ARO:3002897|SAT-4	29.0	93	176	180	1.71e-06	45.1
k141_113329_62	megares|MEG_6169|Drugs|Nucleosides|Streptothricin_acetyltransferase|SAT_1	29.0	93	176	180	1.71e-06	45.1
k141_113329_62	NCBI|WP_000627290.1|1|1|sat4|sat4|acetyltransferase|2|streptothricin|streptothricin|streptothricin_N-acetyltransferase_Sat4|AMR|nucleoside	29.0	93	176	180	1.71e-06	45.1
k141_113329_62	megares|MEG_6166|Drugs|Nucleosides|Streptothricin_acetyltransferase|SAT_1	29.0	93	176	180	1.71e-06	45.1
k141_113329_65	SARG|gi|921979807|ref|WP_053271336.1|	38.0	234	234	648	3.66e-48	166
k141_113329_65	SARG|gi|895865878|ref|WP_048974758.1|	38.6	223	234	646	6.72e-47	163
k141_113329_65	SARG|gb|AAV85982.1|ARO:3000535|macB	35.9	231	234	644	1.26e-46	162
k141_113329_65	SARG|gi|694064328|ref|WP_032410816.1|	37.7	223	234	646	1.73e-45	159
k141_113329_65	SARG|gb|WP_104671188.1|ARO:3003948|efrA	27.4	226	234	575	6.82e-19	84.0
k141_113329_65	SARG|gb|AAK76137.1|ARO:3000024|patA	29.0	210	234	564	1.91e-17	79.7
k141_113329_65	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	28.1	224	234	578	8.80e-17	77.8
k141_113329_65	SARG|gb|AYV52072.1|ARO:3002882|lmrD	25.1	227	234	664	1.90e-15	73.9
k141_113329_65	SARG|gi|493394434|ref|WP_006350564.1|	27.4	226	234	602	8.34e-15	72.0
k141_113329_65	SARG|gi|655401130|ref|WP_028800283.1|	28.9	232	234	599	5.08e-14	69.7
k141_113329_79	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	38.1	226	224	232	3.15e-44	147
k141_113329_79	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	39.0	228	224	232	2.21e-41	139
k141_113329_79	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	39.0	228	224	232	2.21e-41	139
k141_113329_79	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	37.6	234	224	235	2.40e-41	139
k141_113329_79	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.0	226	224	231	2.40e-40	137
k141_113329_79	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.0	226	224	231	3.38e-40	136
k141_113329_79	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	36.7	226	224	229	6.38e-40	135
k141_113329_79	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	37.4	227	224	231	6.73e-40	135
k141_113329_79	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.0	226	224	231	6.73e-40	135
k141_113329_79	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.4	227	224	231	6.73e-40	135
k141_113329_80	CARD|gb|ABD30512.1|ARO:3000839|arlS	32.4	219	552	451	6.69e-28	115
k141_113329_80	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	30.1	219	552	370	5.16e-24	102
k141_113329_80	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	26.2	248	552	392	5.47e-23	100
k141_113329_80	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.9	219	552	381	9.44e-22	96.3
k141_113329_80	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.9	219	552	381	9.44e-22	96.3
k141_113329_80	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.0	219	552	381	5.91e-20	90.9
k141_113329_80	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.0	219	552	381	5.91e-20	90.9
k141_113329_80	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	28.3	219	552	365	7.12e-19	87.4
k141_113329_80	CARD|gb|CYF42523.1|ARO:3004047|kdpD	25.7	202	552	885	3.98e-10	61.6
k141_113329_83	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	35.5	220	238	293	2.02e-45	152
k141_113329_83	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	34.7	222	238	307	1.59e-44	150
k141_113329_83	SARG|gi|500194536|ref|WP_011867743.1|	35.3	221	238	306	2.03e-41	142
k141_113329_92	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	35.3	156	179	223	9.24e-31	110
k141_113329_92	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	34.4	183	179	239	1.14e-28	105
k141_113329_92	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	33.5	176	179	232	1.93e-28	104
k141_113329_92	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	33.0	176	179	231	1.58e-26	99.8
k141_113329_92	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	32.0	181	179	232	2.27e-26	99.4
k141_113329_92	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	32.0	181	179	232	2.27e-26	99.4
k141_113329_92	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	25.6	156	179	225	2.25e-18	78.2
k141_113329_92	CARD|gb|AAC73788.1|ARO:3003841|kdpE	25.6	156	179	225	2.25e-18	78.2
k141_113329_97	SARG|gi|445996722|ref|WP_000074577.1|	39.5	81	161	309	1.11e-12	63.2
k141_113329_97	SARG|gi|445996723|ref|WP_000074578.1|	39.5	81	161	309	1.52e-12	62.8
k141_113329_97	SARG|gi|445996724|ref|WP_000074579.1|	39.5	81	161	309	2.08e-12	62.4
k141_113329_97	SARG|gi|884875933|emb|CKG93789.1|	39.5	81	161	309	2.08e-12	62.4
k141_113329_97	SARG|gi|445996719|ref|WP_000074574.1|	39.5	81	161	309	2.84e-12	62.0
k141_113329_97	SARG|gi|1043490477|ref|WP_065382463.1|	39.5	81	161	309	2.84e-12	62.0
k141_113329_97	SARG|gi|445996726|ref|WP_000074581.1|	39.5	81	161	309	2.84e-12	62.0
k141_113329_97	SARG|gi|446110087|ref|WP_000187942.1|	37.0	92	161	309	2.84e-12	62.0
k141_113329_97	SARG|gi|507054395|ref|WP_016125339.1|	39.5	81	161	309	2.84e-12	62.0
k141_113329_97	SARG|gi|445996709|ref|WP_000074564.1|	38.3	81	161	309	3.90e-12	61.6
k141_113329_98	SARG|gb|APB03219.1|ARO:3003986|TaeA	31.7	63	124	648	2.80e-06	43.9
k141_113329_98	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.3	77	124	655	7.07e-06	42.7
k141_113329_98	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.3	77	124	655	7.07e-06	42.7
k141_113329_98	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.3	77	124	655	7.07e-06	42.7
k141_113329_98	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.3	77	124	655	7.07e-06	42.7
k141_113329_98	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.3	77	124	655	7.07e-06	42.7
k141_113329_98	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.3	77	124	655	7.07e-06	42.7
k141_113329_98	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.3	77	124	655	7.07e-06	42.7
k141_113329_98	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.3	77	124	655	7.07e-06	42.7
k141_113329_98	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.3	77	124	655	7.07e-06	42.7
k141_64013_31	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	27.5	182	313	346	2.37e-14	71.6
k141_5995_4	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	27.6	362	395	712	8.59e-32	126
k141_103369_7	SARG|gb|APB03219.1|ARO:3003986|TaeA	26.9	234	208	648	8.04e-20	85.9
k141_103369_7	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	25.7	191	208	504	4.73e-12	63.2
k141_103369_7	SARG|M80346.gene.p01	35.7	154	208	551	9.99e-11	59.3
k141_103369_7	megares|MEG_1491|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|CARA_1	35.7	154	208	551	9.99e-11	59.3
k141_103369_7	SARG|gi|488338532|ref|WP_002407917.1|	23.0	178	208	498	1.89e-06	46.6
k141_103369_22	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	24.9	831	898	1033	6.31e-77	270
k141_103369_22	SARG|gb|AEY83581|ARO:3000510|mupB	24.9	831	898	1033	6.31e-77	270
k141_103369_22	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	25.0	835	898	1024	9.44e-68	243
k141_103369_22	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	24.8	825	898	1024	1.28e-67	243
k141_103369_22	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	25.0	835	898	1024	3.18e-67	242
k141_103369_22	SARG|gb|CAA53189|ARO:3000521|mupA	24.8	825	898	1024	4.30e-67	241
k141_103369_22	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	25.0	460	898	1107	1.47e-33	138
k141_103369_22	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	25.0	460	898	1107	1.47e-33	138
k141_103369_104	NCBI|WP_050824634.1|1|1|tet(O)|tet(O)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(O)|AMR|tetracycline	36.9	130	401	639	6.34e-16	78.6
k141_103369_105	SARG|L42544.gene.p01	26.8	678	700	651	1.14e-74	252
k141_103369_105	SARG|AAV80410	26.8	678	700	651	2.20e-74	251
k141_103369_105	SARG|NP_348076	27.1	687	700	652	3.09e-72	246
k141_103369_105	SARG|YP_002850805	27.3	684	700	652	5.94e-72	245
k141_103369_105	SARG|ABN80187	27.3	673	700	640	4.55e-70	239
k141_103369_105	SARG|ZP_02952732	26.9	685	700	652	1.11e-69	239
k141_103369_105	SARG|ZP_02632674	26.9	685	700	660	1.29e-69	239
k141_103369_105	SARG|ACI02041	27.3	673	700	639	2.28e-69	238
k141_103369_105	SARG|DQ294299.gene.p01	27.3	673	700	639	2.28e-69	238
k141_103369_105	SARG|L20800.gene.p01	26.9	685	700	652	2.95e-69	238
k141_103369_118	NCBI|WP_005813024.1|1|1|vanW-I|vanW-I||2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-I|AMR|glycopeptide	39.1	128	568	373	2.52e-19	89.0
k141_103369_132	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	25.5	255	649	1033	3.19e-10	62.4
k141_103369_132	SARG|gb|AEY83581|ARO:3000510|mupB	25.5	255	649	1033	3.19e-10	62.4
k141_103369_153	SARG|gb|AAC75089.1|ARO:3003577|ugd	59.1	394	395	388	4.20e-165	467
k141_103369_176	NCBI|WP_049151672.1|1|1|pbp2m|pbp2m||2|beta-lactam|beta-lactam|penicillin-binding_protein_PBP2M|AMR|beta-lactam	28.5	316	466	593	7.80e-22	97.4
k141_16720_11	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	31.6	247	375	355	2.29e-25	104
k141_16720_11	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	31.6	247	375	355	2.29e-25	104
k141_16720_11	SARG|ACM47285	31.6	247	375	363	2.55e-25	104
k141_16720_11	NCBI|WP_049898469.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	32.0	247	375	356	2.90e-24	101
k141_16720_11	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	31.4	258	375	356	2.90e-24	101
k141_16720_11	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	30.3	251	375	355	5.36e-24	100
k141_16720_11	SARG|BAE96115	30.3	251	375	355	5.36e-24	100
k141_16720_11	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	30.5	203	375	209	4.11e-20	86.7
k141_16720_26	megares|MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH_1	45.9	159	162	159	1.45e-44	143
k141_16720_72	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	35.6	219	353	255	7.72e-39	137
k141_16720_72	SARG|gb|APB03219.1|ARO:3003986|TaeA	27.0	233	353	648	1.15e-17	83.2
k141_16720_72	SARG|gb|AAC75271.1|ARO:3003952|yojI	30.2	215	353	547	1.83e-17	82.4
k141_16720_72	SARG|M80346.gene.p01	29.9	184	353	551	1.55e-10	61.2
k141_16720_72	megares|MEG_1491|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|CARA_1	29.9	184	353	551	1.55e-10	61.2
k141_16720_101	SARG|gi|686432388|ref|WP_031921070.1|	22.1	434	587	451	3.76e-18	86.3
k141_16720_101	SARG|gi|1006223553|ref|WP_061745579.1|	21.9	434	587	451	3.76e-18	86.3
k141_16720_101	SARG|gi|686304329|ref|WP_031867798.1|	22.1	434	587	451	3.76e-18	86.3
k141_16720_101	SARG|ZP_03986195	22.1	434	587	451	5.01e-18	85.9
k141_16720_101	SARG|gi|446573695|ref|WP_000651041.1|	22.1	434	587	451	5.01e-18	85.9
k141_16720_101	SARG|gi|446573707|ref|WP_000651053.1|	22.5	436	587	451	6.68e-18	85.5
k141_16720_101	SARG|ZP_04679156	22.1	434	587	451	6.68e-18	85.5
k141_16720_101	SARG|gi|505177635|ref|WP_015364737.1|	23.6	433	587	451	8.90e-18	85.1
k141_16720_101	SARG|gi|537465183|ref|WP_020976941.1|	22.5	436	587	451	1.19e-17	84.7
k141_16720_101	SARG|gi|686408548|ref|WP_031913080.1|	21.9	434	587	451	1.19e-17	84.7
k141_16720_119	SARG|L42544.gene.p01	32.3	635	870	651	5.22e-97	316
k141_16720_119	SARG|AAV80410	32.1	635	870	651	5.22e-97	316
k141_16720_119	SARG|YP_002850805	31.9	623	870	652	2.24e-90	298
k141_16720_119	SARG|ZP_02952732	31.7	621	870	652	3.12e-90	298
k141_16720_119	SARG|ZP_02632674	31.7	621	870	660	3.78e-90	298
k141_16720_119	SARG|L20800.gene.p01	31.7	621	870	652	6.04e-90	297
k141_16720_119	SARG|NP_348076	31.1	623	870	652	1.64e-87	291
k141_16720_119	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	30.0	614	870	641	2.44e-87	290
k141_16720_119	SARG|AAZ79478	30.0	614	870	657	3.57e-87	290
k141_16720_119	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	29.8	614	870	654	1.24e-86	288
k141_16720_155	SARG|gb|CAH14033.1|ARO:3004100|LpeB	26.7	835	1346	1014	2.23e-56	212
k141_16720_155	SARG|gb|AAG05914|ARO:3004075|MuxC	25.2	831	1346	1036	5.61e-55	208
k141_16720_155	CARD|gb|AAC75137.1|ARO:3000794|mdtC	26.3	852	1346	1025	2.57e-52	199
k141_16720_155	ResF|tmexD4_1_CP091084_1	24.7	846	1346	1044	9.18e-49	188
k141_16720_155	CARD|gb|AAG07594.1|ARO:3000808|MexI	24.9	823	1346	1029	3.50e-48	186
k141_16720_155	NCBI|WP_027591160.1|1|1|tmexD2|tmexD|efflux|2|TIGECYCLINE|TETRACYCLINE|multidrug_efflux_RND_transporter_permease_subunit_TMexD2|AMR|tetracycline	24.5	846	1346	1044	6.44e-48	186
k141_16720_155	ResF|tmexD3_1_LC633285_1	24.6	846	1346	1044	4.51e-47	183
k141_16720_155	NCBI|WP_034065037.1|1|1|tmexD3|tmexD|efflux|2|TIGECYCLINE|TETRACYCLINE|multidrug_efflux_RND_transporter_permease_subunit_TMexD3|AMR|tetracycline	24.6	846	1346	1044	4.51e-47	183
k141_16720_155	NCBI|WP_118842627.1|1|1|tmexD1|tmexD|efflux|2|TIGECYCLINE|TETRACYCLINE|multidrug_efflux_RND_transporter_permease_subunit_TMexD1|AMR|tetracycline	24.2	846	1346	1044	1.37e-46	181
k141_16720_155	SARG|gi|757680562|ref|WP_042911120.1|	24.4	844	1346	1043	3.14e-46	180
k141_36917_4	SARG|gb|ABA71733.1|ARO:3002972|vanTG	39.0	374	393	712	3.89e-82	264
k141_36917_4	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	38.5	374	393	712	4.75e-78	253
k141_36917_4	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	35.3	374	393	711	3.44e-66	222
k141_36917_7	SARG|gb|AAB53445.1|ARO:3002897|SAT-4	32.3	93	145	180	1.33e-06	44.7
k141_36917_7	megares|MEG_6169|Drugs|Nucleosides|Streptothricin_acetyltransferase|SAT_1	32.3	93	145	180	1.33e-06	44.7
k141_36917_7	NCBI|WP_000627290.1|1|1|sat4|sat4|acetyltransferase|2|streptothricin|streptothricin|streptothricin_N-acetyltransferase_Sat4|AMR|nucleoside	32.3	93	145	180	1.33e-06	44.7
k141_36917_7	megares|MEG_6166|Drugs|Nucleosides|Streptothricin_acetyltransferase|SAT_1	32.3	93	145	180	1.33e-06	44.7
k141_36917_7	NCBI|WP_063854935.1|1|1|sat4|sat4|acetyltransferase|2|streptothricin|streptothricin|streptothricin_N-acetyltransferase_Sat4|AMR|nucleoside	32.3	93	145	180	1.83e-06	44.3
k141_36917_7	megares|MEG_6165|Drugs|Nucleosides|Streptothricin_acetyltransferase|SAT_1	32.3	93	145	180	1.83e-06	44.3
k141_106706_42	SARG|gb|AYV52072.1|ARO:3002882|lmrD	31.6	494	727	664	1.50e-66	231
k141_106706_42	SARG|gb|AAK76136.1|ARO:3000025|patB	30.2	493	727	588	1.09e-62	219
k141_106706_42	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	29.1	498	727	579	1.42e-58	207
k141_106706_42	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	28.5	492	727	579	4.77e-57	203
k141_106706_42	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	30.5	488	727	579	1.71e-56	201
k141_106706_42	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	29.6	487	727	579	1.15e-55	199
k141_106706_42	SARG|gb|CDO61516.1|ARO:3003949|efrB	34.9	272	727	362	9.01e-50	177
k141_106706_42	SARG|gb|ADZ12699.1|ARO:3005091|RanA	30.7	215	727	258	1.82e-16	79.0
k141_106706_42	NCBI|WP_171943877.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	26.5	189	727	461	1.53e-08	56.6
k141_106706_42	NCBI|WP_172065992.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	25.0	192	727	461	5.65e-07	51.6
k141_9513_1	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	48.2	56	223	346	1.72e-08	52.8
k141_86083_17	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	30.0	686	662	703	5.14e-81	270
k141_86083_42	CARD|gb|ABD30512.1|ARO:3000839|arlS	31.3	227	445	451	8.01e-23	99.4
k141_86083_42	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	28.4	215	445	367	2.55e-21	94.0
k141_86083_42	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	28.4	215	445	368	2.58e-21	94.0
k141_86083_43	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.4	230	236	231	1.27e-43	145
k141_86083_43	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	37.0	230	236	231	3.57e-43	144
k141_86083_43	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	36.4	231	236	232	7.30e-43	144
k141_86083_43	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	35.9	231	236	232	2.05e-42	142
k141_86083_43	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.4	230	236	231	7.92e-42	141
k141_86083_43	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	36.1	230	236	239	9.83e-42	141
k141_86083_43	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	36.4	231	236	233	1.18e-41	140
k141_86083_43	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.1	230	236	231	1.24e-40	138
k141_86083_43	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	32.8	229	236	231	1.75e-40	137
k141_86083_43	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	35.6	233	236	235	1.95e-40	137
k141_86083_47	SARG|gb|AAK76136.1|ARO:3000025|patB	32.2	609	633	588	3.80e-99	313
k141_86083_47	SARG|gb|AYV52072.1|ARO:3002882|lmrD	32.5	550	633	664	2.44e-94	303
k141_86083_47	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	31.1	618	633	579	9.29e-87	281
k141_86083_47	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	31.0	619	633	579	2.69e-85	277
k141_86083_47	SARG|gi|497748188|ref|WP_010062372.1|	30.9	605	633	605	1.52e-82	270
k141_86083_47	SARG|gi|948137056|ref|WP_056795395.1|	30.9	611	633	602	3.87e-82	269
k141_86083_47	SARG|gi|695887424|ref|WP_032788534.1|	30.9	602	633	605	5.81e-82	269
k141_86083_47	SARG|gi|664180077|ref|WP_030714054.1|	30.7	602	633	605	1.13e-81	268
k141_86083_47	SARG|gi|928900436|ref|WP_053931243.1|	29.9	623	633	600	3.85e-81	266
k141_86083_47	SARG|gi|664579989|ref|WP_031094015.1|	29.9	623	633	601	3.94e-81	266
k141_86083_48	SARG|gb|WP_104671188.1|ARO:3003948|efrA	33.2	552	583	575	3.66e-103	322
k141_86083_48	SARG|gb|AAK76137.1|ARO:3000024|patA	34.3	522	583	564	1.78e-100	315
k141_86083_48	SARG|gb|AAK76136.1|ARO:3000025|patB	30.2	483	583	588	1.36e-67	229
k141_86083_48	SARG|gb|AYV52072.1|ARO:3002882|lmrD	28.9	485	583	664	1.14e-66	228
k141_86083_48	SARG|gb|CDO61516.1|ARO:3003949|efrB	36.7	332	583	362	9.79e-64	212
k141_86083_48	SARG|gi|1045390184|ref|WP_065479071.1|	38.5	299	583	605	4.92e-59	206
k141_86083_48	SARG|gi|695865802|ref|WP_032778631.1|	38.5	299	583	605	9.43e-59	205
k141_86083_48	SARG|gi|944470764|ref|WP_055701183.1|	42.6	270	583	601	1.22e-58	205
k141_86083_48	SARG|gi|497748188|ref|WP_010062372.1|	38.1	299	583	605	3.46e-58	204
k141_86083_48	SARG|gi|764446018|ref|WP_044369325.1|	38.1	299	583	605	3.46e-58	204
k141_86083_60	SARG|AAZ79478	36.6	183	607	657	6.47e-28	117
k141_86083_60	megares|MEG_7181|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	36.6	183	607	657	6.47e-28	117
k141_86083_60	SARG|Z21523.gene.p01	36.6	183	607	657	6.47e-28	117
k141_86083_60	megares|MEG_7182|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	36.6	183	607	670	6.75e-28	117
k141_86083_60	SARG|AAB51122	36.6	183	607	670	6.75e-28	117
k141_86083_60	SARG|Q08425	37.2	180	607	641	1.09e-27	117
k141_86083_60	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	37.2	180	607	641	1.09e-27	117
k141_86083_60	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	37.2	180	607	654	1.14e-27	117
k141_86083_60	SARG|BAD46890	36.1	183	607	657	1.15e-27	117
k141_86083_60	SARG|Q52360	36.7	180	607	641	1.93e-27	116
k141_86083_79	SARG|gi|686448604|ref|WP_031928572.1|	25.7	249	270	451	1.40e-19	86.7
k141_86083_79	SARG|gi|446573690|ref|WP_000651036.1|	25.7	249	270	451	3.52e-19	85.5
k141_86083_79	SARG|gi|516415429|ref|WP_017804827.1|	25.7	249	270	451	3.52e-19	85.5
k141_86083_79	SARG|gi|487138435|ref|WP_001629863.1|	26.1	249	270	451	3.52e-19	85.5
k141_86083_79	SARG|gi|537465183|ref|WP_020976941.1|	25.7	249	270	451	4.78e-19	85.1
k141_86083_79	SARG|gi|686123390|ref|WP_031769354.1|	25.7	249	270	451	4.78e-19	85.1
k141_86083_79	SARG|ZP_03986195	25.7	249	270	451	4.78e-19	85.1
k141_86083_79	SARG|gi|446573715|ref|WP_000651061.1|	25.7	249	270	451	4.78e-19	85.1
k141_86083_79	SARG|gi|446573693|ref|WP_000651039.1|	25.7	249	270	451	4.78e-19	85.1
k141_86083_79	SARG|gi|446573692|ref|WP_000651038.1|	25.7	249	270	451	4.78e-19	85.1
k141_86083_84	SARG|gi|1035706844|ref|WP_064548272.1|	37.7	77	940	648	1.20e-08	57.8
